Hung, Yi-Chih
Lin, Che-Chen
Huang, Wei-Lun
Chang, Man-Ping
Chen, Ching-Chu
Article History
Received: 17 March 2016
Accepted: 6 July 2016
First Online: 27 July 2016
Competing interests
: Dr. Ching-Chu Chen and Dr. Yi-Chih Hung have received lecture fee from Merck, Boehringer Ingelheim, AstraZeneca and Novartis, and have been reimbursed by these companies for attending several conferences. These companies manufacture DPP4 inhibitors (sitagliptin, saxagliptin, vildagliptin) for the treatment of type 2 diabetes. Che-Chen Lin, Wei-Lun Huang and Man-Ping Chang have nothing to disclose.